Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
Explore this paper's citation graph
Summary
It is suggested that VEGF content in tumor cytosols is a predictor of RFS and OS in primary node-positive breast cancer in primary NPBC after adjuvant endocrine treatment or adjUvant chemotherapy.
- Type
- article
- Published
- 2000-04-07
- Cited by
- 267
- References
- 38
- OpenAlex
- https://openalex.org/W1925212740
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32302218
Keywords
Medicine, Internal medicine, Vascular endothelial growth factor, Breast cancer, Oncology
References
- Inhibition of angiogenesis by antiestrogens.
- Cancer : Principles and Practice of Oncology
- Progesterone and estrogen receptors as prognostic variables in breast cancer.
- Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells.
- Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
- Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
- Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
- Vascular endothelial growth factor is a secreted angiogenic mitogen.
- Influence of Tumoral Microvessel Density on the Recurrence-Free Survival in Human Breast Cancer: Preliminary Results
- Angiogenesis in cancer, vascular, rheumatoid and other disease
- VEGF and tPA co-expressed in malignant glioma.
- Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
- Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer.
- Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.
- Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
- Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
- Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.
- Microvessel quantitation and prognosis in invasive breast carcinoma.
- Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.
Cited by
- Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
- Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
- Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.
- Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab.
- Vascular Endothelial Growth Factor in Tumor Tissue and Blood Serum from Patients with Breast Cancer
- VEGFおよびVEGF-C高発現を呈し, 急速な転帰をとった結腸内分泌細胞癌の1例
- Role of Vascular Endothelial Growth Factor during Breast Cancer
- Neue molekulare Therapiekonzepte beim Mammakarzinom
- The Effects of Anthropometry and Angiogenesis on Breast Cancer Etiology
- Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging
- Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis
- Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology
- Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer
- Dichotomisation of Continuous Data: Review of Methods, Advantages, and Disadvantages
- Expressão de VEGF em tumores de mama de pacientes submetidas a quimioterapia neoadjuvante
- Anti-angiogenic therapy: Rationale, challenges and clinical studies
- ANJİYOGENEZİN TEMEL MOLEKÜLER MEKANİZMALARI VE TÜMOR ANJİYOGENEZİ
- Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
- Untersuchung des Zusammenhangs zwischen VEGF Gewebsexpression und des Sauerstoffpartialdrucks in primären Mammakarzinomen am Modell der primär systemischen Chemotherapie
- Clinical implications of circulating angiogenic factors in cancer patients.
Related papers
- Research progress of aluminum adjuvant
- Immune Adjuvant Effect of CFNCpG Motif on Antigen of Inactivated BVDV1
- Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine
- Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant
- Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants
- Sanchinoside R1 as An Immunopotentiator of Hepatitis A Vaccine Containing Aluminium Adjuvant
- Observation on the immune effect of subunit vaccine of Toxoplasma gondii with different adjuvants
- Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant–Antigen Codelivery
- Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy